Burden of breast cancer in 29 EEA countries: trends, disparities and public health implications
Abstract
Background: Breast cancer remains the most commonly diagnosed cancer and a leading cause of cancer-related mortality among women in Europe, with notable variation across countries. Despite advances in detection and treatment, modifiable risk factors continue to influence disease burden. This study aims to assess the burden of breast cancer across EEA countries, examining temporal trends and geographic disparities to inform prevention and policy strategies.
Methods: We retrieved rates for disability-adjusted life years (DALYs), incidence, and deaths from the GBD 2023 study for 29 EEA countries (EU-27, Iceland, and Norway; data for Liechtenstein was not available) for females aged 40 to 85+ years, which we then weighted using the European Standard Population 2013 to obtain age-standardized rates (reported per 100,000). In addition, we calculated the estimated annual percentage change (EAPC) with 95% CI for 1990-2023. We conducted all analyses using R4.3.3.
Results: In 2023, the age-adjusted DALY rates for breast cancer ranged between 1,139.7 in Norway and 1,869.0 in Germany while the age-adjusted incidence rate was between 150.2 in Bulgaria and 330.9 in France. Age-adjusted mortality rates ranged between 48.0 in Norway and 84.5 in Denmark. Between 1990 and 2023, the EAPC ranged between -2.75% (95% CI: -2.94% and -2.55%; Denmark) and 0.17% (95% CI: 0.02% and 0.32%; Romania) for DALY rates, -0.88% (95% CI: -1.07% and -0.69%; Denmark) and 2.07% (1.81% and 2.32%; Cyprus) for incidence rates, and -2.21% (95% CI: -2.44% and -1.98%; Denmark) and 0.60% (95% CI: 0.44% and 0.76%; Romania) for mortality rates.
Conclusions: Our findings indicate that the disease burden has not suffered major decreases (reflected in both increases and decreases in the EAPC) highlighting the need for stronger efforts in breast cancer awareness and screening, alongside targeted policies addressing modifiable risk factors such as obesity, physical inactivity, and alcohol consumption.
Key messages: • The burden of breast cancer across EEA countries has not suffered major decreases, although variation exist between countries and burden of disease metrics.
• Targeted action on screening, awareness, and modifiable risk factors is needed to reduce disparities and improve outcomes across the EEA.
Related
- Global burden, geographic and sex disparities, and projections to 2050 for salivary gland cancer across G20 countries: a GLOBOCAN 2024 analysis
- Trends, Risk Factors, and Future Burden of Female Breast Cancer in China and Other G20 Countries, 1990-2050: A Comparative Global Burden of Disease 2023 Analysis.
- Global and regional gastric cancer burden and age-related survival disparities: complementary analyses of GBD 2021 and SEER data
- Symptom burden, Psychosocial Distress, Resilience and Health-Related Quality of Life in Women with Metastatic Breast Cancer Receiving Contemporary Systemic Therapy
- Tumor Clusterin Expression at Diagnosis Is Associated with Residual Disease Burden After Neoadjuvant Chemotherapy in Breast Cancer
BibTeX
@article{grad2026burden,
title = {{Burden of breast cancer in 29 EEA countries: trends, disparities and public health implications}},
author = {DA Grad and B Unim},
journal = {The European Journal of Public Health},
year = {2026},
month = oct,
doi = {10.1093/eurpub/ckag169.613},
url = {https://doi.org/10.1093/eurpub/ckag169.613},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Burden of breast cancer in 29 EEA countries: trends, disparities and public health implications
AU - DA Grad
AU - B Unim
PY - 2026
DA - 2026/10/01
JO - The European Journal of Public Health
DO - 10.1093/eurpub/ckag169.613
UR - https://doi.org/10.1093/eurpub/ckag169.613
AB - Background: Breast cancer remains the most commonly diagnosed cancer and a leading cause of cancer-related mortality among women in Europe, with notable variation across countries. Despite advances in detection and treatment, modifiable risk factors continue to influence disease burden. This study aims to assess the burden of breast cancer across EEA countries, examining temporal trends and geographic disparities to inform prevention and policy strategies. Methods: We retrieved rates for disability-adjusted life years (DALYs), incidence, and deaths from the GBD 2023 study for 29 EEA countries (EU-27, Iceland, and Norway; data for Liechtenstein was not available) for females aged 40 to 85+ years, which we then weighted using the European Standard Population 2013 to obtain age-standardized rates (reported per 100,000). In addition, we calculated the estimated annual percentage change (EAPC) with 95% CI for 1990-2023. We conducted all analyses using R4.3.3. Results: In 2023, the age-adjusted DALY rates for breast cancer ranged between 1,139.7 in Norway and 1,869.0 in Germany while the age-adjusted incidence rate was between 150.2 in Bulgaria and 330.9 in France. Age-adjusted mortality rates ranged between 48.0 in Norway and 84.5 in Denmark. Between 1990 and 2023, the EAPC ranged between -2.75% (95% CI: -2.94% and -2.55%; Denmark) and 0.17% (95% CI: 0.02% and 0.32%; Romania) for DALY rates, -0.88% (95% CI: -1.07% and -0.69%; Denmark) and 2.07% (1.81% and 2.32%; Cyprus) for incidence rates, and -2.21% (95% CI: -2.44% and -1.98%; Denmark) and 0.60% (95% CI: 0.44% and 0.76%; Romania) for mortality rates. Conclusions: Our findings indicate that the disease burden has not suffered major decreases (reflected in both increases and decreases in the EAPC) highlighting the need for stronger efforts in breast cancer awareness and screening, alongside targeted policies addressing modifiable risk factors such as obesity, physical inactivity, and alcohol consumption. Key messages: • The burden of breast cancer across EEA countries has not suffered major decreases, although variation exist between countries and burden of disease metrics. • Targeted action on screening, awareness, and modifiable risk factors is needed to reduce disparities and improve outcomes across the EEA.
SN - 1101-1262
SN - 1464-360X
ER -